___

• Arda-Pirincci P. and Bolkent S. (2011) The role of glucagon-like peptide-2 on apoptosis, cell proliferation, and oxidant-antioxidant system at a mouse model of intestinal injury induced by tumor necrosis factor-alpha /actinomycin D. Molecular and Cellular Biochemistry, 350:13-27.
• Benali N., Ferjoux G., Puente E., Buscail L., Susuni C. (2000) Somatostatin receptors. Digestion, 62: 27-32.
• Boushey R.P., Yusta B., Drucker D.J. (1999) Glucagon-like mortality and reduces the severity of indomethacin-induced American Endocrinology and Metabolism,277(40): 937-47. decreases murine of Journal Physiology
• Buchman A.L., Katz S., Fang J.C., Bernstein C.N., Abou-Assi S.G., for the Teduglutide Study Group. (2010) Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflammatory Bowel Diseases, 16: 962-73. Chandra R. and Liddle Cholecystokinin. Curr Opin Endocrinol Diabetes Obes, 14: 63-7. R.A. (2007)
• Chang Q. and Teppermann B.L. (2001) The role of protein kinase C isozymes in TNF- α-induced cytotoxicity to a rat intestinal epithelial cell line. American Journal of Physiology-Gastrointestinal Physiology, 280: 572-83. and Liver
• Chang Q. and Teppermann B.L. (2003) Effect of selective PKC İsoform activation and inhibition on TNF-α-induced injury and apoptosis in human intestinal epithelial cells. British Journal of Pharmacology, 140: 41-52.
• De Haan J.J., Lubbers T., Hadfoune M., Luyer M.D., Dejong C.H., Greve JW. (2008) Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. Annals of Surgery, 248: 842-8.
• De Jonge F., Van Nassauw L., De Man J.G., De Winter B.Y., Van Meir F., Depoortere I., Peeters T.L., Pelckmans P.A., Van Marcks E., Timmermans J.P. (2003) Effects of schistosoma somatostatin and somatostatin receptor 2A expression Neurogastroenterology and Motility, 15: 149-59. ınfection on in mouse ileum.
• Drucker D.J., Ehrlich P., Asa S.L., Brubaker P.L. (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide-2. Proceedings of The National Academy of Sciences of The United States of America, 3: 7911-6.
• Drucker D.J. (2005) Biologic actions and therapeutic potential of the proglucagon- derived peptides. Nature Clinical Practice Endocrinology & Metabolism, 1: 22-31.
• Estall J.L. and Drucker D.J. (2003) Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. Journal of Nutrition, 133: 3708-11.
• Estall J.L and Drucker D.J. (2005) Tales beyond the crypt: glucagon-like peptide-2 and cytoprotection in the intestinal mucosa. Endocrinology, 146: 19-21.
• Ferjoux G., Bousquet C., Cordelier P., Benali N., Lopez F., Rochaix P., Buscail L., Susini C. somatostatin controlling cell proliferation. Journal of Physiology-Paris, 94: 205-10. of receptors negatively D Actinomycin deoxyribonucleic acid-dependent synthesis of ribonucleic acid. Science, 136: 315-6.
• Green D.W., Gomez G., Greeley G.H. (1989) Gastrointestinal peptides. Gastroenterology Clinics of North America, 18: 695-733.
• Ivory C.P., Wallace , Mccafferty D.M., Sigalet D.L. (2008) Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide Physiology-Gastrointestinal Physiology, 295: G1202-10. Journal and Liver
• Jeppesen P.B., Sanguinetti E.L., Buchman A., Howard L., Scolapio J.S., Ziegler T.R., Gregory J., Tappenden K.A., Holst J., Mortensen P.B. (2005) Teduglutide (ALX- 0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut, 54: 1224-31.
• Jones B.E., Lo C.R., Liu H., Srinivasan A., Streetz K., Valentino K.L., Czaja M.J. (2000) Hepatocytes sensitized to tumor necrosis factor-alpha cytotoxicity undergo apoptosis through caspase-dependent and caspase-independent pathways. Journal of Biological Chemistry, 275: 705-12.
• Kunstle G., Leist M., Uhlig S., Revesz L., Feifel R., Mackenzie A., Wendel A. (1997) Ice-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α. Immunology Letters, 55: 5-10.
• Leist M., Gantner F., Bohlinger I., Germann P.G., Tiegs G., Wendel A.(1994) Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-α requires transcriptional arrest. Journal of Immunology, 153: 1778- 88.
• Leist M., Gantner F., Naumann H., Bluethmann H., Vogt K., Brigelius-Flohe R., Nicotera P., Volk H. (1997) Tumor necrosis factor- induced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology, 112: 923-34.
• L’Heureux M.C. and Brubaker P.L. (2003) Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. Journal of Pharmacology and Experimental Therapeutics, 306:347-354.
• Martin G.R., Wallace L.E., Sigalet D.L. (2004) Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. American Journal of Physiology-Gastrointestinal Physiology, 286: G964-72. and Liver
• Mueller C. (2002) Tumour necrosis factor in mouse inflammation. Immunology, 105: 1-8.
• Panteris V., Kouroumalis E. Somatostatin and inflammation. (2007) In: Rarley EP, ed. Progress in neuropeptide research. New York: Nova science publishers, 642-48.
• Paran D. and Paran H. (2003) Somatostatin analogs in rheumatoid arthritis and other inflammatory conditions. Investigational Drugs, 4: 578-82. Opinion in
• Pastorino J.G., Simbula G., Yamamoto K., Glascott P.A., Rothman R.J., Farber J.L. (1996) The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial Journal 271:29792-8. transition. Chemistry, of
• Remick D.G. and Kunkel S.L. (1993) Pathophysiologic alterations induced by tumor necrosis factor. International Review of Experimental Pathology, 3: 7-25.
• Sawicki S.G. and Godman G.C. (1971) On the differential cytotoxicity of actinomycin D. Journal of Cell Biology, 50: 746-61.
• Schwartz H.S. and Sodergren J.E. (1968) Actinomycin D effects on nucleic acids during tumor regression. Cancer Research, 28: 445-51
• Schwartz H.S., Sternberg S.S., Philips F.S. (1963) Pharmacology of mitomycin C. IV. Effects in vivo on nucleic acid synthesis; comparison with actinomycin D. Cancer Research, 23: 1125-37.
• Sinclair E.M. and Drucker D.J. (2005) Proglucagon-derived peptides: mechanisms of Physiology, 20: 357-65. potential.
• Tavakkolizadeh A., Shen R., Abraham P., Kormi N., Seifert P., Edelman E.R., Jacops D.O., Zinner M.J., Ashley S.W., Whang E.E. (2000) Glucagon-like peptide-2: a new treatment enteritis. Journal of Surgical Research, 91: 77-82.
• chemotherapy-induced
• Thomas R.P., Hellmich M.R., Townsend C.M., Evers B.M. (2003) Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocrine Reviews, 24: 571-99.
• Van Horssen R., Ten Hagen T.L.M., Eggermont A.M.M. (2006) TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist, 11: 397-408.
• Yusta B., Huang L., Munroe D., Wolff G., Fantaske R., Sharma S., Demchyshyn L., Asa Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology, 119: 744-55. (2000)